MarketPulse

Phase 3 clinical trial failure

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

Gossamer Bio Stock Collapses 80% on Trial Data Disclosure; Securities Lawsuit Filed

Gossamer Bio faces securities fraud lawsuit after stock plummets 80% following disclosure of allegedly undisclosed Latin American trial site enrollment practices that compromised Phase 3 study results. Lead plaintiff deadline is June 1, 2026.
GOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Gainey Mckenna & Egleston

Gossamer Bio Faces Class Action Over Failed PAH Study, Stock Plummets 80%

Gossamer Bio ($GOSS) faces class action lawsuit over failed PROSERA PAH trial; stock crashed 80% to $0.42 per share on February 23, 2026, amid allegations of misleading investor statements.
GOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Ultragenyx Stock Plunges 42% After Setrusumab Phase 3 Failure; Class Action Deadline Nears

Ultragenyx faces securities fraud lawsuit after setrusumab Phase 3 failure triggered 42% stock decline. Lead plaintiff applications due April 6, 2026.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Ultragenyx Faces Class Action Over Failed Drug Trials; Investors Have Until April 6 Deadline

Ultragenyx ($RARE) faces class action lawsuit over failed setrusumab Phase 3 trials, with stock down 42%. Investors have until April 6, 2026 to seek lead plaintiff status.
RAREsecurities fraudclass action lawsuit